Celadon Pharmaceuticals
Plc
("Celadon" or the "Company"
or the "Group")
Second Admission of
Shares
London, 07 June 2024 - Celadon
Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company
focused on the development, production and sale of breakthrough
cannabis-based medicines, is pleased to announce that further to
the announcement on 10 May 2024,
application for the admission of 238,095 new ordinary shares to
trading on AIM (the "Second Admission") has been made. It is
expected the shares will be admitted to trading on 11 June
2024.
The remaining 476,191 shares are due
to be admitted in two further instalments on 15 July and 12 August
2024.
The Company advises that on
Admission the Company's issued share capital will consist of
65,982,712 Ordinary Shares, with one voting right each. The Company
does not hold any shares in treasury. Therefore, the total number
of Ordinary Shares and voting rights in the Company will be
65,982,712. This figure may be used by shareholders in the Company
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
|
|
|
|
Celadon Pharmaceuticals Plc
|
|
|
James Short
Jonathan Turner
|
Via Powerscourt
|
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and
Broker)
|
|
|
Bobbie Hilliam / Andrew
Potts
|
+44 (0)20 7523 8000
|
|
|
|
|
Global Investment Strategy UK Limited (Joint
Broker)
James
Sheehan
|
+44 (0)20 7048 9400
|
|
|
|
|
Powerscourt Group
|
|
|
Sarah MacLeod / Nick Johnson / Sam
Austrums
|
+44 (0)20 7250 1446
|
|
|
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK
based pharmaceutical company focused on the research, cultivation,
manufacturing, and sale of breakthrough cannabis-based medicines.
Its primary focus is on improving quality of life for chronic pain
sufferers, as well as exploring the potential of cannabis-based
medicines for other conditions such as autism. Its 100,000 sq. ft
UK facility is EU-GMP approved and comprises indoor hydroponic
cultivation, proprietary GMP extraction and manufacturing and an
analytical and R&D laboratory. Celadon's Home Office licence
allows for the commercial supply of its GMP pharmaceutical cannabis
product. The Group owns an approved clinical trial using cannabis
based medicinal products to treat chronic pain in the UK. Celadon
also has a minority interest in early-stage biopharma Kingdom
Therapeutics which is developing a licensed cannabinoid medicine to
treat children with Autism Spectrum Disorder.
For further information please visit
our website www.celadonpharma.co.uk